{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:05Z","timestamp":1791252725045,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":2261,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1093\/annonc\/mdt194","type":"journal-article","created":{"date-parts":[[2013,5,31]],"date-time":"2013-05-31T05:00:57Z","timestamp":1369976457000},"page":"2402-2408","source":"Crossref","is-referenced-by-count":128,"title":["Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial"],"prefix":"10.1016","volume":"24","author":[{"given":"A.","family":"Bahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Oudard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u00d6zg\u00fcro\u011dlu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kocak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gravis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Devin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.O.","family":"Sartor;","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt194_bb0010","doi-asserted-by":"crossref","unstructured":"ZMalikGdi LorenzoMBasaranCabazitaxel (Cbz) + prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): interim results from compassionate-use programme (CUP) and early-access programme (EAP). European Society of Medical Oncology Congress28 September\u20132 October, 2012 Vienna, AustriaPoster 931P","DOI":"10.1016\/S0923-7534(20)33490-6"},{"key":"10.1093\/annonc\/mdt194_bb0015","series-title":"JEVTANA\u00ae (cabazitaxel) Injection, Summary of Product Characteristics","author":"Sanofi","year":"2013"},{"key":"10.1093\/annonc\/mdt194_bb0020","unstructured":"Sanofi U.S. LLCJEVTANA\u00ae (cabazitaxel) Injection, Prescribing InformationBridgewater, NJ, USA, 2010. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/201023lbl.pdf (4 April 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdt194_bb0025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt194_bb0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2217\/fon.11.23","article-title":"TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer","volume":"7","author":"Oudard","year":"2011","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0035","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12032-010-9495-2","article-title":"Health-related quality of life assessment in prospective trials of systemic cytotoxic chemotherapy for metastatic castration resistant prostate cancer: which instrument we need?","volume":"28","author":"Colloca","year":"2011","journal-title":"Med Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0040","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.suponc.2011.06.003","article-title":"Documenting the symptom experience of cancer patients","volume":"9","author":"Deshields","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0045","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1200\/JCO.2005.04.0543","article-title":"Peripheral neuropathy induced by microtubule-stabilizing agents","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0050","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/0304-3959(75)90044-5","article-title":"The McGill Pain Questionnaire: major properties and scoring methods","volume":"1","author":"Melzack","year":"1975","journal-title":"Pain"},{"key":"10.1093\/annonc\/mdt194_bb0055","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1200\/JCO.1996.14.6.1756","article-title":"Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points","volume":"14","author":"Tannock","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0060","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt194_bb0065","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0070","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt194_bb0075","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1038\/sj.bjc.6605053","article-title":"Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group","volume":"100","author":"Apolone","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1093\/annonc\/mdt194_bb0080","author":"Heidenreich","year":"2012","journal-title":"EAU Guidelines on Prostate Cancer"},{"key":"10.1093\/annonc\/mdt194_bb0085","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1200\/JCO.1999.17.8.2506","article-title":"Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study","volume":"17","author":"Kantoff","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0090","unstructured":"National Comprehensive Cancer Network. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Prostate Cancer (Version 2.2013)http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf (4 April 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdt194_bb0095","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0100","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/annonc\/mds585","article-title":"Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy","volume":"24","author":"Sternberg","year":"2013","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1093\/annonc\/mdt194_bb0105","doi-asserted-by":"crossref","first-page":"LBA4512","DOI":"10.1200\/jco.2012.30.15_suppl.lba4512","article-title":"Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA)","volume":"30","author":"Parker","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt194_bb0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1477-7525-9-88","article-title":"Pain in castration-resistant prostate cancer with bone metastases: a qualitative study","volume":"9","author":"Gater","year":"2011","journal-title":"Health Qual Life Outcomes"},{"key":"10.1093\/annonc\/mdt194_bb0115","series-title":"TAXOTERE\u00ae (docetaxel) Injection Concentrate, Intravenous Infusion (IV) Prescribing Information","author":"Sanofi U.S. LLC","year":"2010"},{"key":"10.1093\/annonc\/mdt194_bb0120","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1078-0432.CCR-09-2514","article-title":"Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer","volume":"16","author":"Armstrong","year":"2010","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419369388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/9\/2402\/13789831\/mdt194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T07:42:41Z","timestamp":1624693361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419369388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0923753419369388"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt194","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}